Revenue ($USD): $410,921,000
R&D spend: $46,610,000.00
Employees: 1,793
Fiscal year end: 12/31/22
CEO: Quentin Blackford
CEO Quentin Blackford said iRhythm will “continue to redefine the standard of cardiac care and demonstrate our unique value proposition to customers, patients, and payers.”
iRhythm has also faced challenges. In May, it received anFDA warning letterinvolving the Zio AT. The same month, itdisclosed its third subpoenafrom federal investigators; company officials say they’re cooperating.–CN